239 related articles for article (PubMed ID: 22027607)
1. [Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
Kulua TK; Fedorova NV; Popovkina OA
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9 Pt 2):45-50. PubMed ID: 22027607
[TBL] [Abstract][Full Text] [Related]
2. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
[TBL] [Abstract][Full Text] [Related]
3. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
[TBL] [Abstract][Full Text] [Related]
4. [The use of stalevo in the treatment of patients with Parkinson's disease].
Kretova AS; Lyubimov AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):35-8. PubMed ID: 25591514
[TBL] [Abstract][Full Text] [Related]
5. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
6. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
8. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
9. [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
Fedorova NV; Levin OS; Smolentseva IG; Kulua TK
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):39-46. PubMed ID: 17069061
[TBL] [Abstract][Full Text] [Related]
10. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
11. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
13. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Klivényi P; Vécsei L
Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774
[TBL] [Abstract][Full Text] [Related]
14. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
[TBL] [Abstract][Full Text] [Related]
15. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
Boiko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EY; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaitsev KA; Kostenko EV
Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
[TBL] [Abstract][Full Text] [Related]
16. [Long term experience with Stalevo in Szeged, Hungary].
Klivényi P; Vécsei L
Ideggyogy Sz; 2009 May; 62(5-6):178-80. PubMed ID: 19579666
[TBL] [Abstract][Full Text] [Related]
17. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Martínez-Martín P; Hernández B; Ricart J;
Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
[TBL] [Abstract][Full Text] [Related]
18. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Titova NV; Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
